• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Section 32 Raises $740 Million Venture Fund

    11/4/21 8:14:00 AM ET
    $COIN
    $CRWD
    $EXAS
    $RLAY
    Finance: Consumer Services
    Finance
    Computer Software: Prepackaged Software
    Technology
    Get the next $COIN alert in real time by email

    SAN DIEGO, Nov. 4, 2021 /PRNewswire/ -- Section 32 announced today the closing of its fourth fund, raising approximately $740 million from returning and new investors. Investors in Fund 4 include leading philanthropic and non-profit organizations, educational endowments and foundations, and leaders from the technology and healthcare sectors. Section 32 Fund 4 will support companies across all stages that are pioneering innovations at the forefront of technology and healthcare. With the closing of its oversubscribed Fund 4 and to support its continued growth, Section 32 also announced the appointment of Nina Labatt to the role of Chief Operating Officer and Chief Financial Officer.

    Section 32 is a venture capital fund investing at the frontiers of technology and healthcare.

    "I'm so pleased that Nina has joined this team and I look forward to what this growing group will achieve together," commented Bill Maris, founder of Section 32. "What a privilege it is to close this fourth fund, and to thus have the continued opportunity to try to use capital as a lever to accelerate the profound positive impact technology can have on healthcare and humanity."

    The closing of Fund 4 brings assets under management for Section 32 to over $1.8B. To-date, Section 32 has made investments in more than 70 companies including Coinbase (NASDAQ:COIN), Crowdstrike (NASDAQ:CRWD), Relay Therapeutics (NASDAQ:RLAY), Thrive Earlier Detection (NASDAQ:EXAS), and Vir Biotechnology (NASDAQ:VIR). Section 32 has made eight investments from Fund 4 following an initial close of the fund in July 2021.

    Since its inception in 2017, Section 32 has grown to 16 people, including four managing partners: Bill Maris, Michael Pellini, M.D., Steve Kafka, Ph.D., and Andy Harrison, with offices in San Diego, Silicon Valley and Boston, MA. The team's cumulative career experience includes contributing to more than 130 company exits (through acquisition or public offerings) and helping to build and finance more than 50 companies with valuations in excess of $1 billion.

    With the closing of Fund 4, Section 32 added Nina Labatt to its team as its chief operating officer and chief financial officer. Nina brings more than two decades of experience to her new role and is recognized as an industry expert leading finance and operations in venture capital and private equity.

    "I'm delighted to join the team at Section 32 at this exciting time in the firm's growth," commented Nina Labatt. "I look forward to collaborating with the team to continue building world-class operations and finance functions that support our investing efforts."

    Most recently, Nina served as chief operating officer and general partner at Trinity Ventures, where she managed finance, marketing, data analytics, human resources, and legal for the firm. She also led internal strategic initiatives, structured and executed investment transactions with the investing team and participated in the firm's fundraising efforts. Previously, Ms. Labatt served as managing director, Private Equity Services for Silicon Valley Bank, as well as chief financial officer for Health Evolution Partners. Earlier in her career, Ms. Labatt was an investment banker for Goldman Sachs and Montgomery Securities. Ms. Labatt received a bachelor's degree in economics and a master's degree in international policy studies from Stanford University. She received her MBA from Harvard Business School. She was a founding member of the Northern California board of directors for the CFO Leadership Council and previously served as chairperson of the board of directors of VCBC, a non-profit association for finance professionals in venture capital.

    About Section 32

    Section 32 is a venture capital fund investing at the frontiers of technology and healthcare. Founded by Bill Maris, the team has vast experience building iconic companies. The firm's goal is to improve the human condition by accelerating the discovery, development and distribution of important technologies and life-saving medicines. Section 32 invests across the entirety of technology and life sciences. This includes software, cybersecurity, advanced communications and computation, space, climate change related technologies, machine learning, artificial intelligence, biotechnology, therapeutics, advanced diagnostics, precision medicine, genomics and more. For more information, please visit Section32.com

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/section-32-raises-740-million-venture-fund-301416494.html

    SOURCE Section 32

    Get the next $COIN alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $COIN
    $CRWD
    $EXAS
    $RLAY

    CompanyDatePrice TargetRatingAnalyst
    Coinbase Global Inc.
    $COIN
    7/28/2025Buy → Neutral
    Monness Crespi & Hardt
    Coinbase Global Inc.
    $COIN
    7/23/2025Buy
    Erste Group
    CrowdStrike Holdings Inc.
    $CRWD
    7/17/2025$465.00Neutral
    Macquarie
    Coinbase Global Inc.
    $COIN
    7/14/2025$400.00Buy
    Argus
    CrowdStrike Holdings Inc.
    $CRWD
    7/14/2025$495.00Overweight → Equal-Weight
    Morgan Stanley
    Coinbase Global Inc.
    $COIN
    7/10/2025$300.00Buy → Sell
    H.C. Wainwright
    CrowdStrike Holdings Inc.
    $CRWD
    7/7/2025Overweight → Neutral
    Piper Sandler
    Coinbase Global Inc.
    $COIN
    6/25/2025$310.00 → $510.00Outperform
    Bernstein
    More analyst ratings

    $COIN
    $CRWD
    $EXAS
    $RLAY
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Relay Therapeutics Inc.

      SCHEDULE 13G/A - Relay Therapeutics, Inc. (0001812364) (Subject)

      7/29/25 2:22:24 PM ET
      $RLAY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Vir Biotechnology Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Vir Biotechnology, Inc. (0001706431) (Filer)

      7/24/25 9:05:39 AM ET
      $VIR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 144 filed by Vir Biotechnology Inc.

      144 - Vir Biotechnology, Inc. (0001706431) (Subject)

      7/17/25 4:18:37 PM ET
      $VIR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $COIN
    $CRWD
    $EXAS
    $RLAY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Coinbase Global downgraded by Monness Crespi & Hardt

      Monness Crespi & Hardt downgraded Coinbase Global from Buy to Neutral

      7/28/25 8:37:01 AM ET
      $COIN
      Finance: Consumer Services
      Finance
    • Erste Group initiated coverage on Coinbase Global

      Erste Group initiated coverage of Coinbase Global with a rating of Buy

      7/23/25 8:54:24 AM ET
      $COIN
      Finance: Consumer Services
      Finance
    • Macquarie initiated coverage on CrowdStrike with a new price target

      Macquarie initiated coverage of CrowdStrike with a rating of Neutral and set a new price target of $465.00

      7/17/25 8:07:14 AM ET
      $CRWD
      Computer Software: Prepackaged Software
      Technology

    $COIN
    $CRWD
    $EXAS
    $RLAY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Conroy Kevin T bought $1,001,325 worth of shares (19,500 units at $51.35), increasing direct ownership by 2% to 1,074,191 units (SEC Form 4)

      4 - EXACT SCIENCES CORP (0001124140) (Issuer)

      11/13/24 12:56:28 PM ET
      $EXAS
      Medical Specialities
      Health Care

    $COIN
    $CRWD
    $EXAS
    $RLAY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Vir Biotechnology Initiates Second Pivotal Trial in Its Global ECLIPSE Registrational Program for Chronic Hepatitis Delta

      First patient enrolled in ECLIPSE 2 Phase 3 clinical trial evaluating the switch to the combination of tobevibart and elebsiran in patients not achieving undetectable hepatitis delta virus RNA despite bulevirtide treatment ECLIPSE 2 is a pivotal trial designed to support global marketing applications, including in the U.S. and Europe Vir Biotechnology, Inc. (NASDAQ:VIR) today announced the enrollment of the first participant in the ECLIPSE 2 Phase 3 clinical trial, which is designed to compare the combination of tobevibart and elebsiran to continued bulevirtide monotherapy in participants with chronic hepatitis delta (CHD) who have not achieved undetectable hepatitis delta virus (HDV

      7/31/25 8:05:00 AM ET
      $VIR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Exact Sciences and Humana Expand Colorectal Cancer Screening Partnership with Cologuard Plus™ Test

      Cologuard Plus™ Available In-Network August 2025 Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced an expanded partnership with Humana Inc. to enhance access to colorectal cancer (CRC) screening. Through the partnership, the Cologuard Plus™ test will be available as an in-network service for eligible Humana Medicare Advantage members nationwide beginning in August 2025. Humana, the fourth largest private insurer in the United States, has approximately 5.8 million Medicare Advantage members. "The Exact Sciences team is proud to expand access to Cologuard Plus through our collaboration with Humana, making it easier for more

      7/31/25 7:00:00 AM ET
      $EXAS
      Medical Specialities
      Health Care
    • JPMorganChase and Coinbase Launch Strategic Partnership to Make Buying Crypto Easier than Ever

      New direct bank-to-wallet link, Chase Ultimate Rewards transfer, and the ability to use Chase credit cards, will give users more ways than ever to get into crypto Today, JPMorganChase (NYSE:JPM) and Coinbase (NASDAQ:COIN) announced a strategic partnership that sets a new standard for customer choice and security in the innovation economy. This collaboration introduces features designed to enhance access and optionality for our mutual customers. The initial phase of the partnership includes new features for mutual customers, including: Direct Bank-to-Wallet Connection: Through JPMorgan's secure API, Chase customers will be able to seamlessly link their bank accounts to Coinbase wallet

      7/30/25 8:22:00 AM ET
      $COIN
      $JPM
      Finance: Consumer Services
      Finance
      Major Banks

    $COIN
    $CRWD
    $EXAS
    $RLAY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Catinazzo Thomas sold $74,000 worth of shares (20,081 units at $3.69), decreasing direct ownership by 6% to 335,295 units (SEC Form 4)

      4 - Relay Therapeutics, Inc. (0001812364) (Issuer)

      7/30/25 4:54:19 PM ET
      $RLAY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Officer Rahmer Peter sold $62,947 worth of shares (17,083 units at $3.68), decreasing direct ownership by 4% to 377,998 units (SEC Form 4)

      4 - Relay Therapeutics, Inc. (0001812364) (Issuer)

      7/30/25 4:54:35 PM ET
      $RLAY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President, R&D Bergstrom Donald A sold $113,478 worth of shares (30,770 units at $3.69), decreasing direct ownership by 5% to 552,720 units (SEC Form 4)

      4 - Relay Therapeutics, Inc. (0001812364) (Issuer)

      7/30/25 4:54:05 PM ET
      $RLAY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $COIN
    $CRWD
    $EXAS
    $RLAY
    Financials

    Live finance-specific insights

    See more
    • Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2025 Financial Results on August 6, 2025

      Vir Biotechnology, Inc. (NASDAQ:VIR), today announced that the Company will provide a corporate update and report financial results for the second quarter ended June 30, 2025, on August 6, 2025. The Company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on August 6, 2025. The corporate update and financial results will be provided via a press release shortly after market close and will be accessible on the News page in the Investors section of the Vir Biotechnology website. Participants may access the conference call via webcast on the Events & Presentations page of the Vir Biotechnology website or via phone by dialing the U.S. toll free number +1 (888) 800-8770 or internation

      7/22/25 4:05:00 PM ET
      $VIR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Exact Sciences Schedules Second Quarter 2025 Earnings Call

      Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2025 financial results after the close of the U.S. financial markets on August 6, 2025. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. Second quarter 2025 webcast & conference call details Date: Wednesday, August 6, 2025 Time: 5 p.m. ET Webcast: The live webcast can be accessed at www.exactsciences.com Telephone: Domestic callers, dial 888-330-2384 International callers, d

      7/14/25 6:00:00 AM ET
      $EXAS
      Medical Specialities
      Health Care
    • Sequans Launches Bitcoin Treasury Program with Initial Acquisition of 370 BTC

      Paris, France--(Newsfile Corp. - July 10, 2025) - Sequans Communications S.A. (NYSE:SQNS), a leading provider of cellular IoT semiconductors, today announced the acquisition of 370 bitcoin as part of its newly launched bitcoin treasury strategy. The purchase was funded using an initial portion of the net proceeds from the Company's recent offering of ordinary shares and convertible debentures, which closed on July 7, 2025. "We are excited to begin executing our strategic plan to accumulate over 3,000 BTC in the coming weeks," said Georges Karam, CEO of Sequans. "This initiative reflects our confidence in bitcoin as a long-term store of value for our shareholders"To support this initiative, S

      7/10/25 6:43:00 AM ET
      $COIN
      $SQNS
      Finance: Consumer Services
      Finance
      Semiconductors
      Technology

    $COIN
    $CRWD
    $EXAS
    $RLAY
    Leadership Updates

    Live Leadership Updates

    See more
    • Dataminr Appoints Tiffany Buchanan as Chief Financial Officer to Accelerate Strategic Growth and Public Market Readiness

      Former CrowdStrike finance leader brings deep expertise in scaling high-growth technology companies, and will partner with Dataminr's leadership team to drive global expansion and operational scale  NEW YORK, June 26, 2025 /PRNewswire/ -- Dataminr, the leading real-time AI platform, today announced the appointment of Tiffany Buchanan as Chief Financial Officer. Buchanan is a highly accomplished executive with a proven track record of accelerating growth, leading IPO readiness, and operating at scale in the public market. Drawing upon more than 20 years of experience leading g

      6/26/25 9:00:00 AM ET
      $CRWD
      Computer Software: Prepackaged Software
      Technology
    • Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors

      CAMBRIDGE, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced the appointment of Claire Mazumdar, Ph.D., to the Company's Board of Directors, effective June 9, 2025. "It is a privilege to welcome Claire to our Board, where she will draw from her strategic and operational experience in clinical-stage oncology to offer guidance as we prepare to initiate our Phase 3 ReDiscover-2 trial in breast cancer soon," said Sanjiv Patel, M.D., President and Chief Executive Officer of Relay Therapeutics.

      6/11/25 4:05:00 PM ET
      $BCAX
      $RLAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • CrowdStrike Appoints Brad Burns as Chief Communications Officer

      Former Salesforce and Snowflake CCO to drive comms strategy for CrowdStrike's next phase of growth and innovation CrowdStrike (NASDAQ:CRWD) today announced the appointment of Brad Burns as chief communications officer (CCO). Burns will lead the company's global communications strategy, supporting executive leadership as CrowdStrike accelerates its growth and scale as cybersecurity's platform innovator for the AI era. "CrowdStrike's mission to stop breaches has never been more important. As adversaries weaponize AI – lowering the bar to launch and scale attacks – communicating the power of the Falcon platform to defeat modern threats is critical to businesses around the world," said George

      5/13/25 8:01:00 AM ET
      $CRWD
      Computer Software: Prepackaged Software
      Technology

    $COIN
    $CRWD
    $EXAS
    $RLAY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Coinbase Global Inc.

      SC 13G/A - Coinbase Global, Inc. (0001679788) (Subject)

      11/14/24 5:44:24 PM ET
      $COIN
      Finance: Consumer Services
      Finance
    • Amendment: SEC Form SC 13G/A filed by Coinbase Global Inc.

      SC 13G/A - Coinbase Global, Inc. (0001679788) (Subject)

      11/14/24 5:40:50 PM ET
      $COIN
      Finance: Consumer Services
      Finance
    • Amendment: SEC Form SC 13G/A filed by CrowdStrike Holdings Inc.

      SC 13G/A - CrowdStrike Holdings, Inc. (0001535527) (Subject)

      11/14/24 1:22:38 PM ET
      $CRWD
      Computer Software: Prepackaged Software
      Technology